| Revision as of 02:03, 26 May 2018 editDoc James (talk | contribs)Administrators312,258 edits interesting← Previous edit | Revision as of 02:04, 26 May 2018 edit undoDoc James (talk | contribs)Administrators312,258 edits adjustedNext edit → | ||
| Line 3: | Line 3: | ||
| Evidence from two large studies in 2017 showed that the transfusion of blood from younger donors to older people was either no different from, or led to worse outcomes than, blood from older donors.<ref name=sbm>{{cite news|last1=Novella|first1=Steven|title=Parabiosis – The Next Snakeoil|url=https://sciencebasedmedicine.org/parabiosis-the-next-snakeoil/|work=Science-Based Medicine|date=3 August 2016}}</ref><ref name=Garraud2017>{{cite journal|last1=Garraud|first1=O|title=Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?|journal=Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis|date=August 2017|volume=56|issue=4|pages=635-636|doi=10.1016/j.transci.2017.07.002|pmid=28780993}}</ref> Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; studies had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.<ref>{{cite journal|last1=Ning|first1=S|last2=Heddle|first2=NM|last3=Acker|first3=JP|title=Exploring donor and product factors and their impact on red cell post-transfusion outcomes.|journal=Transfusion medicine reviews|date=January 2018|volume=32|issue=1|pages=28-35|doi=10.1016/j.tmrv.2017.07.006|pmid=28988603}}</ref> | Evidence from two large studies in 2017 showed that the transfusion of blood from younger donors to older people was either no different from, or led to worse outcomes than, blood from older donors.<ref name=sbm>{{cite news|last1=Novella|first1=Steven|title=Parabiosis – The Next Snakeoil|url=https://sciencebasedmedicine.org/parabiosis-the-next-snakeoil/|work=Science-Based Medicine|date=3 August 2016}}</ref><ref name=Garraud2017>{{cite journal|last1=Garraud|first1=O|title=Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?|journal=Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis|date=August 2017|volume=56|issue=4|pages=635-636|doi=10.1016/j.transci.2017.07.002|pmid=28780993}}</ref> Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; studies had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.<ref>{{cite journal|last1=Ning|first1=S|last2=Heddle|first2=NM|last3=Acker|first3=JP|title=Exploring donor and product factors and their impact on red cell post-transfusion outcomes.|journal=Transfusion medicine reviews|date=January 2018|volume=32|issue=1|pages=28-35|doi=10.1016/j.tmrv.2017.07.006|pmid=28988603}}</ref> | ||
| The evidence suggesting the treatment could be beneficial was based on research done on rodents at ] in which blood transfused from young mice seemed to invigorate older mice;<ref name=Garraud2017/> the circulatory systems of the mice were connected which put them in a state of ].<ref name=sbm/ |
The evidence suggesting the treatment could be beneficial was based on research done on rodents at ] in which blood transfused from young mice seemed to invigorate older mice;<ref name=Garraud2017/> the circulatory systems of the mice were connected which put them in a state of ].<ref name=sbm/> | ||
| Human trials are reported to be underway in China and Korea but with very little detail about what is actually involved.<ref name="Inc" /> | |||
| ==Availability== | ==Availability== | ||
| A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a ], to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/><ref>{{cite news|last1=Haynes|first1=Gavin|title=Ambrosia: the startup harvesting the blood of the young|url=https://www.theguardian.com/society/shortcuts/2017/aug/21/ambrosia-the-startup-harvesting-the-blood-of-the-young|accessdate=23 May 2018|work=The Guardian|date=21 August 2017|language=en}}</ref> The startup was started by Karmazin who has an MD but is not able to practice medicine as he has no license to do so.<ref name=Max2017>{{cite web|last1=Maxmen|first1=Amy|title=This startup takes cash from aging adults in exchange for young people’s blood|url=https://www.technologyreview.com/s/603242/questionable-young-blood-transfusions-offered-in-us-as-anti-aging-remedy/|website=MIT Technology Review|accessdate=26 May 2018|language=en}}</ref> Another physician who is involved, David Wright is involved with doing intravenous treatments of vitamins and antibiotics for non traditional purposes.<ref name=Max2017/> A bioethicist from McGill suggests that Ambrosia is running this trial as they would be unable to get FDA approval to sell this treatment otherwise.<ref name=Max2017/> | A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a ], to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/><ref>{{cite news|last1=Haynes|first1=Gavin|title=Ambrosia: the startup harvesting the blood of the young|url=https://www.theguardian.com/society/shortcuts/2017/aug/21/ambrosia-the-startup-harvesting-the-blood-of-the-young|accessdate=23 May 2018|work=The Guardian|date=21 August 2017|language=en}}</ref> The startup was started by Karmazin who has an MD but is not able to practice medicine as he has no license to do so.<ref name=Max2017>{{cite web|last1=Maxmen|first1=Amy|title=This startup takes cash from aging adults in exchange for young people’s blood|url=https://www.technologyreview.com/s/603242/questionable-young-blood-transfusions-offered-in-us-as-anti-aging-remedy/|website=MIT Technology Review|accessdate=26 May 2018|language=en}}</ref> Another physician who is involved, David Wright is involved with doing intravenous treatments of vitamins and antibiotics for non traditional purposes.<ref name=Max2017/> A bioethicist from McGill suggests that Ambrosia is running this trial as they would be unable to get FDA approval to sell this treatment otherwise.<ref name=Max2017/> | ||
| A company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company ] to create a ]-based experimental ] drug, which they propose to test on people with ].<ref name=Trends2017>{{cite journal|last1=de Magalhães|first1=JP|last2=Stevens|first2=M|last3=Thornton|first3=D|title=The Business of Anti-Aging Science.|journal=Trends in biotechnology|date=November 2017|volume=35|issue=11|pages=1062-1073|doi=10.1016/j.tibtech.2017.07.004|pmid=28778607}} {{open access}}</ref><ref>{{cite journal|last1=Drew|first1=L|title=Neuroscience: The power of plasma.|journal=Nature|date=27 September 2017|volume=549|issue=7673|pages=S26-S27|doi=10.1038/549S26a|pmid=28953857}}</ref> Human trials are reported to be underway in China and Korea but with very little detail about what is actually involved.<ref name="Inc" /> | |||
| ==References== | ==References== | ||
Revision as of 02:04, 26 May 2018
Young blood transfusion refers to transfusing blood specifically from a young person into an older person with the intention of creating a medicinal benefit. The scientific community currently views the practice as little more than snake oil. There have been no human trials published about the technique.
Evidence from two large studies in 2017 showed that the transfusion of blood from younger donors to older people was either no different from, or led to worse outcomes than, blood from older donors. Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; studies had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.
The evidence suggesting the treatment could be beneficial was based on research done on rodents at Stanford University in which blood transfused from young mice seemed to invigorate older mice; the circulatory systems of the mice were connected which put them in a state of parabiosis.
Availability
A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a clinical trial, to see if such transfusions lead to changes in the blood of recipients. The startup was started by Karmazin who has an MD but is not able to practice medicine as he has no license to do so. Another physician who is involved, David Wright is involved with doing intravenous treatments of vitamins and antibiotics for non traditional purposes. A bioethicist from McGill suggests that Ambrosia is running this trial as they would be unable to get FDA approval to sell this treatment otherwise.
A company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company Grifols to create a blood plasma-based experimental biologic drug, which they propose to test on people with Alzheimer's. Human trials are reported to be underway in China and Korea but with very little detail about what is actually involved.
References
- ^ Novella, Steven (3 August 2016). "Parabiosis – The Next Snakeoil". Science-Based Medicine.
- Robbins, Rebecca. "Young-Blood Transfusions Are on the Menu at Society Gala". Scientific American. Retrieved 26 May 2018.
- ^ Garraud, O (August 2017). "Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?". Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 56 (4): 635–636. doi:10.1016/j.transci.2017.07.002. PMID 28780993.
- Ning, S; Heddle, NM; Acker, JP (January 2018). "Exploring donor and product factors and their impact on red cell post-transfusion outcomes". Transfusion medicine reviews. 32 (1): 28–35. doi:10.1016/j.tmrv.2017.07.006. PMID 28988603.
- ^ de Magalhães, JP; Stevens, M; Thornton, D (November 2017). "The Business of Anti-Aging Science". Trends in biotechnology. 35 (11): 1062–1073. doi:10.1016/j.tibtech.2017.07.004. PMID 28778607.
- Haynes, Gavin (21 August 2017). "Ambrosia: the startup harvesting the blood of the young". The Guardian. Retrieved 23 May 2018.
- ^ Maxmen, Amy. "This startup takes cash from aging adults in exchange for young people's blood". MIT Technology Review. Retrieved 26 May 2018.
- Drew, L (27 September 2017). "Neuroscience: The power of plasma". Nature. 549 (7673): S26 – S27. doi:10.1038/549S26a. PMID 28953857.
- Bercovici, Jeff. "Peter Thiel Is Very, Very Interested In Young People's Blood". Inc. Retrieved 5 May 2018.
Further reading
- Makin, Simon (21 April 2017). "Fountain of Youth? Young Blood Infusions "Rejuvenate" Old Mice". Scientific American. Retrieved 5 May 2018.